Human Epidermal Growth Factor Receptor 2 (HER2) is a member of the EGFR kinase family, which also includes HER1, HER3, and HER4.

This article summarized the latest R&D progress of Fezolinetant, the Mechanism of Action for Fezolinetant, and the drug target R&D trends for Fezolinetant.

Nektar Therapeutics disclosed fresh clinical results concerning rezpegaldesleukin utilised for patients battling atopic dermatitis, featuring new clinical effectiveness parameters from its Phase 1b research.

This article summarized the latest R&D progress of Faricimab, the Mechanism of Action for Faricimab, and the drug target R&D trends for Faricimab.

HDAC (Histone Deacetylase), otherwise known as a histone deacetylase, is an important type of enzyme involved in the process of histone modifications.

This article summarized the latest R&D progress of Entrectinib, the Mechanism of Action for Entrectinib, and the drug target R&D trends for Entrectinib.

Coeptis Therapeutics delivers an update on the safety and dosage from Phase 1 Trials of DVX201, intended for those with Relapsed/Refractory AML or High Risk MDS.

This article summarized the latest R&D progress of Daprodustat, the Mechanism of Action for Daprodustat, and the drug target R&D trends for Daprodustat.

GnRHR, or Gonadotropin-Releasing Hormone Receptor, plays a crucial role in the human body's reproductive system.

This article summarized the latest R&D progress of Colecalciferol, the Mechanism of Action for Colecalciferol, and the drug target R&D trends for Colecalciferol.

Alzheon, Inc. reported that their Phase 2 study of ALZ-801 resulted in reduced neural degradation, stabilized brain function, and improved cognition in initial Alzheimer's patients with the apolipoprotein ε4 allele over two years of treatment.

This article summarized the latest R&D progress of Camptothecin, the Mechanism of Action for Camptothecin, and the drug target R&D trends for Camptothecin.